Cannabis Finally Got Rescheduled. Nine Public Operators Went Under Waiting.
Nine publicly traded US cannabis operators have collapsed since 2024, through receivership, creditor protection, forced asset sales or delisting, while the industry waited on federal rescheduling.
Watch the story

Nine publicly traded US cannabis operators have collapsed since 2024, through receivership, creditor protection, forced asset sales or delisting, while the industry waited on federal rescheduling. Together they had about $1.4 billion in annual revenue.
Rescheduling finally arrived for medical cannabis in April 2026. It hasn't rescued the survivors' stocks. MSOS, the largest US cannabis ETF, closed at $4.34 on October 9, down 8.1% for the year, after selling off on almost every piece of good news it got.
About the numbers: share prices are Yahoo Finance daily closes through October 9, 2026. Revenue is each company's last reported twelve months (periods differ; see the note under the table). Company facts come from filings, court records and press releases linked below. This is reporting, not investment advice.
Watch the story

The timeline: buy the rumor, sell the order

December 2025: the executive order. MSOS closed at $3.76 on December 11. Over the next four sessions it rallied to $6.69 on reports that President Trump would order rescheduling. He signed the order on December 18. MSOS touched $7.25 that day, its 52-week high, then closed at $4.89, down 27% on the day the industry got what it asked for. The order directed the Attorney General to finish rescheduling. It said nothing about banking.
January to March: the wait. The promised end-of-first-quarter timeline slipped. MSOS fell 26% in a month, per a January 18 report. On March 30 it closed at $3.15, its low for the year. Its first quarter was down 23.5% on net asset value, per AdvisorShares.
April 23: the Schedule III order. MSOS ran up 62% from that March 30 low to $5.11 on April 22. On April 23 the Justice Department announced a final order, effective April 28. It moved FDA-approved cannabis drugs, and cannabis sold under a qualifying state medical license, to Schedule III. Everything else, including adult-use cannabis, stayed in Schedule I. MSOS touched $5.59 and closed at $4.22, down 17%.
The scope is what traders sold. The federal 280E tax rule, which bars cannabis companies from deducting normal business expenses, no longer applies to state medical licensees. It still applies to adult-use stores. The SAFE Banking Act, reintroduced in June, hasn't passed. Interstate commerce is still illegal. For a multi-state operator with large adult-use sales, like Curaleaf, the order helps only part of the business.
June: the listings. The year's high came in early June. MSOS closed at $5.75 on June 8. On June 10, Trulieve listed on the New York Stock Exchange as TRLV, the first US plant-touching cannabis company to trade there. To qualify, it moved its adult-use business, Harvest, into a separate company, kept only non-voting units in it, and sold a 10% stake carrying all the voting rights to an outside investor for about $14.8 million. The listed company consolidates only its 206 medical dispensaries. Glass House followed on June 30 after a similar split of its retail stores. Curaleaf (1-for-3, June 5) and Verano (1-for-5, June 11) did reverse splits to prepare for US listings of their own.
June 29 to July 15: the hearing. A DEA administrative law judge held hearings on moving the rest of cannabis, including adult-use, to Schedule III. MSOS drifted from $5.08 at the end of June to about $4 by late July, with no deadline set for the judge's recommendation.
September 29: the stay. On September 23, the Government Accountability Office released a report finding that the DEA and FDA lack comprehensive written policies for scheduling drugs. Three parties opposed to rescheduling asked the judge to add it to the hearing record. On September 29, Chief Administrative Law Judge Derek Julius stayed the proceeding to consider it. MSOS fell 11% the next day, to $4.52. Trulieve closed down 12% and Jushi's US-listed shares fell 24%.
Responses are due October 13, and no date is set for a decision. The stay doesn't touch the April medical order. A separate challenge to that order in the D.C. Circuit is moving slowly: on October 9 the Justice Department and the challengers proposed a briefing schedule that runs to February 2027, with oral argument after that.
Nine operators that didn't make it
None of these companies failed because of the rescheduling timeline alone. Most borrowed heavily at high rates during the 2021 boom, then ran into falling prices and a 280E tax bill that drained their cash. Rescheduling was supposed to fix that model. For these nine, it came too late or covered too little.
| Company | Where it operated | What happened | When | Last reported annual revenue |
|---|---|---|---|---|
| Ayr Wellness | FL, NJ, NV, VA, PA, OH, MA, IL, CT | CCAA; core businesses transferred to its noteholders' company, Arboretum | Cease-traded Jun 2025; CCAA Nov 2025; transfers Apr–Oct 2026 | $452.9M |
| The Cannabist Company (Columbia Care) | VA, OH, DE, CO, IL, NJ, MA, WV and others | Note default; CCAA plus US Chapter 15; sold off state by state | Default Jan 2026; CCAA Mar 24, 2026 | $349.8M |
| Gold Flora | CA | Voluntary receivership; 12 stores sold to Stiiizy for $25M | Mar 27, 2025 | ~$124.8M |
| TILT Holdings | MA, OH, PA (plus vape hardware) | CCAA; existing shares to be cancelled | CCAA Nov 7, 2025; delisted Nov 18, 2025 | $115.6M |
| Schwazze | CO, NM | Foreclosure sale won by Vireo Growth; remainder wound down | Auction Nov 2025; closed Mar 2026 | $174.9M* |
| StateHouse (Harborside) | CA | Receivership; parent bankruptcy | Oct 2024; CSE delisting Jun 2025 | $103.7M |
| 4Front Ventures | IL, MA | US units in receivership; parent bankruptcy | May–Jun 2025; CSE delisting Jan 16, 2026 | $75.6M |
| Body and Mind | CA, IL, NV, NJ (pending) | Cease-traded; selling its stores | Jan 2025 onward | $23.0M |
| Lowell Farms | CA | Exited cultivation; suspended, then delisted | CSE delisting May 4, 2026 | $19.2M |
Revenue is each company's last reported twelve months, per StockAnalysis and company filings, so periods differ: several companies stopped filing in 2024. TILT is its fiscal 2024 revenue. Gold Flora is the twelve months to September 30, 2024. *Schwazze has said its 2023 financial statements, audited by a firm the SEC later barred, should not be relied on.
Ayr Wellness
Ayr was one of the larger multi-state operators, with more than 60 dispensaries in Florida alone. It missed its first-quarter 2025 filing deadline and was cease-traded in June 2025. In July 2025 it agreed with its senior noteholders to hand over its core operations, and the parent entered court protection in British Columbia on November 17, 2025, per Insolvency Insider. Virginia moved to the noteholders' company, Arboretum, in April 2026. Florida, New Jersey and Nevada followed on June 2, and the first Ohio transfer closed on October 1. The stores still operate. Shareholders got nothing: AYRWF last traded for under half a cent.
The Cannabist Company
The company formerly known as Columbia Care missed a December 31, 2025 interest payment on about $179 million of senior secured notes, which became a default in January 2026. It filed for CCAA protection in Ontario on March 24, 2026, about a month before the Schedule III order. On May 9 a Delaware court granted it Chapter 15 recognition, making it the first multistate cannabis operator to get protection from a US bankruptcy court.
Cannabist is being sold off by state. Its Virginia business closed a $130 million sale to Parma Holdco in February. It agreed to sell Ohio to Holistic for $47 million. Vireo Growth agreed in July to buy the Colorado, Illinois, Massachusetts, New Jersey and West Virginia operations for up to $35 million, and on October 6 Spherex agreed to buy two Colorado grow facilities. The Ontario court approved the Vireo sale on August 18, with closings staged state by state into 2027.
Schwazze
Schwazze ran dispensaries in Colorado and New Mexico. It stopped filing financial reports and was moved to the OTC Expert Market in July 2024. Vireo Growth bought up its defaulted notes, about $91 million of them for roughly $62 million, per New Cannabis Ventures, and used that debt to win a foreclosure auction in November 2025. Vireo's purchase of 24 Colorado and 21 New Mexico dispensaries closed in March 2026. The rest of Schwazze is being wound down.
TILT Holdings
TILT ran cannabis operations in Massachusetts, Ohio and Pennsylvania alongside a vape-hardware business. It entered CCAA on November 7, 2025, under a restructuring agreement that cancels the existing shares and hands new equity to its senior noteholders. It was delisted from Cboe Canada on November 18.
Gold Flora, StateHouse and Lowell Farms
California took out three operators. Gold Flora entered voluntary receivership on March 27, 2025, after defaulting on an $11.5 million loan, blaming liabilities inherited from its 2023 merger with TPCO. Stiiizy won 12 of its dispensaries at auction for $25 million.
StateHouse, owner of Harborside and Urbn Leaf, owed its lender Pelorus more than $140 million. A receiver took over in October 2024, and the parent filed for bankruptcy listing $176.7 million in liabilities, per Insolvency Insider. We couldn't confirm who bought its assets.
Lowell Farms exited cultivation in 2024, was suspended by the Canadian Securities Exchange and was delisted on May 4, 2026.
4Front Ventures and Body and Mind
4Front's US subsidiaries asked a Massachusetts court to appoint a receiver on May 22, 2025, and its Illinois dispensaries and 250,000-square-foot cultivation site were put up for sale. We found no announced buyer. As of June 30, 2026, 4Front owed its landlord, Innovative Industrial Properties, $32.3 million, and TILT owed it $7.6 million, per IIP's quarterly filing.
Body and Mind has been under a British Columbia cease-trade order since January 2025 for failing to file audited financials, and has been selling its dispensaries one at a time.
Who's left, and who's buying
The stores didn't disappear. Somebody else runs them now, usually a lender or a bigger competitor.
Vireo Growth is the clearest winner. In one year it took Schwazze's 45 stores, agreed to buy most of Cannabist's remaining states, closed its purchase of C21 Investments in August and signed a merger with Planet 13. The noteholders behind Arboretum now own Ayr's Florida business outright.
The survivors are splitting into two groups. Trulieve, Curaleaf and Green Thumb each reported between $69 million and $98 million of adjusted EBITDA in the second quarter, and all three are on or heading to US exchanges. Curaleaf, up 24% this year through October 9, has also made a hostile bid for Aurora Cannabis, which it raised on October 5 to about US$5 a share (0.4013 Curaleaf shares plus US$1 in cash) and extended to December 4. Aurora has reportedly held merger talks with Organigram, which neither company has confirmed. Cresco Labs (down 48% this year) and Vireo itself (down 49%) have been punished for buying while the market waits on Washington.
The next date to watch is October 13, when the parties respond on the GAO report. After the judge issues a recommendation, the DEA still has to publish a final rule. Until it does, adult-use cannabis is Schedule I.
Sources
- White House: Executive order "Increasing Medical Marijuana and Cannabidiol Research" (Dec 18, 2025)
- 24/7 Wall St.: MSOS ETF drops 26% in one month (Jan 18, 2026)
- AdvisorShares: MSOS quarterly portfolio commentary
- Federal Register: Rescheduling of FDA-approved products and state-licensed medical marijuana (2026-08176)
- Sen. Merkley: Bipartisan senators reintroduce cannabis banking reform (June 2026)
- CRB Monitor: Trulieve's uplisting to the New York Stock Exchange
- Trulieve 8-K: Harvest restructuring (June 3, 2026)
- Glass House Brands: Uplist to the NYSE
- GAO-26-108623: Drug scheduling, DEA and HHS need comprehensive policies (Sept 23, 2026)
- Mugglehead: DEA rescheduling hearing stayed over GAO report (Sept 2026)
- Marijuana Moment: Briefing schedule agreed in D.C. Circuit rescheduling lawsuit (Oct 9, 2026)
- Ayr Wellness: Restructuring support agreement with senior noteholders (July 30, 2025)
- Insolvency Insider: Ayr Wellness parent files for CCAA protection
- Ayr Wellness: Florida, New Jersey and Nevada operations transferred to Arboretum (June 2026)
- Ayr Wellness: Completion of Ohio asset transfer (Oct 1, 2026)
- CRB Monitor: Delaware court grants Chapter 15 protection to Cannabist (May 2026)
- Cannabis Business Times: Cannabist closes $130 million sale of Virginia assets
- Vireo Growth: Agreement to acquire Cannabist assets in five states (July 2026)
- Cannabis Business Times: Spherex acquires two Colorado cultivation facilities from Cannabist (Oct 2026)
- FTI Consulting (Cannabist CCAA monitor): Court orders, incl. Remaining States Sale Approval Order (Vireo), Aug 18, 2026
- Schwazze: Transition to OTC Expert Market and delayed filings (July 2024)
- New Cannabis Ventures: Vireo Growth buys $91 million of Schwazze converts for $62 million
- Vireo Growth (CSE Form 10): Schwazze asset acquisition closed (March 2026)
- TILT Holdings: Restructuring support agreement with senior noteholders (Nov 2025)
- Gold Flora: Voluntary receivership (SEC exhibit)
- Ganjapreneur: Stiiizy acquires 12 Gold Flora dispensaries for $25M at auction
- Insolvency Insider: StateHouse Holdings bankruptcy
- 4Front Ventures: All subsidiaries file for court-appointed receiver (May 2025)
- Innovative Industrial Properties 10-Q (quarter ended June 30, 2026)
- Body and Mind: Cease-trade order announcement (Jan 2025)
- Vireo Growth: Closing of C21 Investments acquisition (Aug 2026)
- Vireo Growth: Merger agreement with Planet 13 (July 2026)
- Curaleaf: Notice of variation, change and extension of its offer for Aurora (Oct 6, 2026)